文献速递神经免疫

依库珠单抗在视神经脊髓炎谱系疾病中的应用:来自欧洲队列的常规临床实践数据

Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort.
PubMed 文献 · Neurology · 2024-10-01

本研究回顾性评估了52例AQP4-IgG阳性视神经脊髓炎谱系疾病(NMOSD)患者在接受依库珠单抗(ECU)治疗期间的疗效与安全性。结果显示,ECU治疗期间88%的患者无发作,年化发作率(AAR)中位数从治疗前2年的1.0降至0(p < 0.001),EDSS评分保持稳定(中位数6.0);但7例(19%)在接种脑膜炎球菌疫苗后不久出现发作,7例(13%)发生严重感染,5例(10%)死亡。

要点

  • ECU治疗期间88%的AQP4-IgG+ NMOSD患者无发作,AAR中位数从1.0降至0(p < 0.001)。
  • 未同时口服泼尼松的疫苗接种者中19%在接种后中位9天出现发作。
  • 7例(13%)发生严重感染,5例(10%)死亡,其中4例年龄>60岁且EDSS≥7。

核心结论

  • 依库珠单抗在预防NMOSD发作方面有效。
  • 必须考虑ECU开始前接种脑膜炎球菌疫苗后发作风险增加以及ECU治疗期间可能致命的系统性感染,尤其是有合并症的患者。
  • 需要进一步研究以探索脑膜炎球菌疫苗接种的最佳时机。

研究设计与样本

  • 回顾性评估2014年12月至2022年4月期间在德国20个和奥地利1个大学中心接受ECU治疗的AQP4-IgG+ NMOSD患者,通过病历审查收集数据。
  • 共纳入52例患者(87%女性,年龄55.0 ± 16.3岁),ECU治疗时间为16.2个月(四分位距9.6-21.7)。
  • 主要结局为有效性(年化发作率[AAR]、MRI活动性、残疾变化[EDSS])和安全性(包括不良事件、死亡率和脑膜炎球菌疫苗接种后的发作),采用描述性统计分析。

主要发现

  • 45例(87%)患者在开始ECU前接种脑膜炎球菌疫苗,其中9例同时口服泼尼松,36例未同时口服泼尼松;后者中7例(19%)在接种后不久出现发作(中位9天,四分位距6-10天)。
  • 在开始ECU前口服泼尼松期间接种疫苗的9例患者以及ECU治疗期间(再)接种疫苗的25例患者中,未发生接种后发作。
  • ECU治疗期间88%的患者无发作;AAR中位数从ECU前2年的1.0(范围0-4)降至0(范围0-0.8;p < 0.001)。
  • EDSS评分从开始到末次随访保持稳定(中位数6.0),脑和脊髓新发T2增强或钆增强MRI病灶的患者比例下降。
  • 7例(13%)发生严重感染;5例(10%;中位年龄53.7岁)在ECU治疗期间死亡(1例心肌梗死,1例肠梗阻继发脓毒症,3例系统性感染包括1例脑膜炎球菌脓毒症),其中4例年龄>60岁且开始ECU时严重残疾(EDSS评分≥7);总停药率为19%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Attack prevention is crucial in managing neuromyelitis optica spectrum disorders (NMOSDs). Eculizumab (ECU), an inhibitor of the terminal complement cascade, was highly effective in preventing attacks in a phase III trial of aquaporin-4 (AQP4)-IgG seropositive(+) NMOSDs. In this article, we evaluated effectiveness and safety of ECU in routine clinical care. METHODS: We retrospectively evaluated patients with AQP4-IgG+ NMOSD treated with ECU between December 2014 and April 2022 at 20 German and 1 Austrian university center(s) of the Neuromyelitis Optica Study Group (NEMOS) by chart review. Primary outcomes were effectiveness (assessed using annualized attack rate [AAR], MRI activity, and disability changes [Expanded Disability Status Scale {EDSS}]) and safety (including adverse events, mortality, and attacks after meningococcal vaccinations), analyzed by descriptive statistics. RESULTS: Fifty-two patients (87% female, age 55.0 ± 16.3 years) received ECU for 16.2 (interquartile range [IQR] 9.6 - 21.7) months. Forty-five patients (87%) received meningococcal vaccination before starting ECU, 9 with concomitant oral prednisone and 36 without. Seven of the latter (19%) experienced attacks shortly after vaccination (median: 9 days, IQR 6-10 days). No postvaccinal attack occurred in the 9 patients vaccinated while on oral prednisone before starting ECU and in 25 (re-)vaccinated while on ECU. During ECU therapy, 88% of patients were attack-free. The median AAR decreased from 1.0 (range 0-4) in the 2 years preceding ECU to 0 (range 0-0.8; p < 0.001). The EDSS score from start to the last follow-up was stable (median 6.0), and the proportion of patients with new T2-enhancing or gadolinium-enhancing MRI lesions in the brain and spinal cord decreased. Seven patients (13%) experienced serious infections. Five patients (10%; median age 53.7 years) died on ECU treatment (1 from myocardial infarction, 1 from ileus with secondary sepsis, and 3 from systemic infection, including 1 meningococcal sepsis), 4 were older than 60 years and severely disabled at ECU treatment start (EDSS score ≥ 7). The overall discontinuation rate was 19%. DISCUSSION: Eculizumab proved to be effective in preventing NMOSD attacks. An increased risk of attacks after meningococcal vaccination before ECU start and potentially fatal systemic infections during ECU-particularly in patients with comorbidities-must be considered. Further research is necessary to explore optimal timing for meningococcal vaccinations. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that eculizumab reduces annualized attack rates and new MRI lesions in AQP4-IgG+ patients with NMOSD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Ringelstein M, Asseyer S, Lindenblatt G, et al. Eculizumab Use in Neuromyelitis Optica Spectrum Disorders: Routine Clinical Care Data From a European Cohort. Neurology. 2024. PMID: 39353149. doi:10.1212/WNL.0000000000209888

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。